IN2014DN10408A - - Google Patents
Info
- Publication number
- IN2014DN10408A IN2014DN10408A IN10408DEN2014A IN2014DN10408A IN 2014DN10408 A IN2014DN10408 A IN 2014DN10408A IN 10408DEN2014 A IN10408DEN2014 A IN 10408DEN2014A IN 2014DN10408 A IN2014DN10408 A IN 2014DN10408A
- Authority
- IN
- India
- Prior art keywords
- methods
- antigen
- increasing
- immune cells
- specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012902345A AU2012902345A0 (en) | 2012-06-05 | Vaccination with Interleukin-4 Antagonists | |
PCT/AU2013/000589 WO2013181696A1 (en) | 2012-06-05 | 2013-06-05 | Vaccination with interleukin-4 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN10408A true IN2014DN10408A (de) | 2015-08-14 |
Family
ID=49711200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN10408DEN2014 IN2014DN10408A (de) | 2012-06-05 | 2013-06-05 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20150150963A1 (de) |
EP (2) | EP2854837A4 (de) |
JP (1) | JP2015520175A (de) |
KR (1) | KR20150021088A (de) |
CN (1) | CN104717971A (de) |
AU (1) | AU2013271338B2 (de) |
BR (1) | BR112014030436A2 (de) |
CA (1) | CA2875683A1 (de) |
HK (1) | HK1203358A1 (de) |
IL (1) | IL236092A0 (de) |
IN (1) | IN2014DN10408A (de) |
NZ (1) | NZ702721A (de) |
SG (1) | SG11201408101TA (de) |
WO (1) | WO2013181696A1 (de) |
ZA (1) | ZA201409076B (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019505554A (ja) * | 2016-02-19 | 2019-02-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによるワクチンの有効性を増強する方法 |
CN113527485A (zh) * | 2020-04-17 | 2021-10-22 | 上海麦济生物技术有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
JP3282188B2 (ja) | 1991-06-27 | 2002-05-13 | 日本電気株式会社 | 半導体メモリ装置 |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
DE69435169D1 (de) | 1993-03-31 | 2009-01-02 | Zeon Corp | Polypeptid, dafür kodierende DNA, diese DNA beinhaltender, rekombinanter Vektor, Herstellung eines rekombinanten Virus unter Verwendung dieses Vektors und dessen Anwendung |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
CN1112943C (zh) | 1994-01-21 | 2003-07-02 | 粉剂注射疫苗股份有限公司 | 气体驱动的基因送递装置 |
GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
US6265387B1 (en) | 1995-10-11 | 2001-07-24 | Mirus, Inc. | Process of delivering naked DNA into a hepatocyte via bile duct |
US6465634B1 (en) | 1996-04-05 | 2002-10-15 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
AU3447097A (en) | 1996-07-01 | 1998-01-21 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant adenovirus |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
CA2316414A1 (en) | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
US6972013B1 (en) | 1998-07-13 | 2005-12-06 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
US7608273B2 (en) | 1998-08-12 | 2009-10-27 | University Of Western Ontario | Recombinant lentivirus encoding modified GP 120 signal sequences |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
JP4693244B2 (ja) | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
AU778698B2 (en) | 1999-04-29 | 2004-12-16 | Miltenyi Biotec B.V. & Co. KG | Method and means for producing high titer, safe, recombinant lentivirus vectors |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US7125705B2 (en) | 2000-04-28 | 2006-10-24 | Genzyme Corporation | Polynucleotides for use in recombinant adeno-associated virus virion production |
SI1407033T1 (sl) | 2002-05-16 | 2006-06-30 | Bavarian Nordic As | Intergenske regije kot insercijska mesta v genomumodificiranega virusavakcinije Ankara (MVA) |
AU2003263653A1 (en) | 2002-09-27 | 2004-04-19 | Daewoong Co., Ltd. | A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus |
US8287879B2 (en) * | 2003-10-16 | 2012-10-16 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
US8048404B1 (en) | 2005-01-04 | 2011-11-01 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles for protein drug delivery |
US7541046B1 (en) | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US7611690B2 (en) | 2005-01-04 | 2009-11-03 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
CA2605924A1 (en) | 2005-04-24 | 2006-11-02 | Acambis Inc. | Recombinant flavivirus vaccines |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
MX2008008968A (es) * | 2006-01-11 | 2008-09-10 | Aerovance Inc | Metodos y composiciones para tratar asma en primates humanos y no humanos. |
US20090068195A1 (en) * | 2007-04-23 | 2009-03-12 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
US20120088814A1 (en) * | 2009-03-31 | 2012-04-12 | Isis Pharmaceuticals, Inc. | Methods of modulating an immune response to a viral infection |
WO2011003138A1 (en) * | 2009-07-06 | 2011-01-13 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
-
2013
- 2013-06-05 CA CA2875683A patent/CA2875683A1/en not_active Abandoned
- 2013-06-05 JP JP2015515352A patent/JP2015520175A/ja active Pending
- 2013-06-05 CN CN201380040156.6A patent/CN104717971A/zh active Pending
- 2013-06-05 AU AU2013271338A patent/AU2013271338B2/en active Active
- 2013-06-05 KR KR20147037109A patent/KR20150021088A/ko not_active Application Discontinuation
- 2013-06-05 EP EP13800233.2A patent/EP2854837A4/de not_active Withdrawn
- 2013-06-05 NZ NZ702721A patent/NZ702721A/en not_active IP Right Cessation
- 2013-06-05 US US14/405,704 patent/US20150150963A1/en not_active Abandoned
- 2013-06-05 SG SG11201408101TA patent/SG11201408101TA/en unknown
- 2013-06-05 BR BR112014030436A patent/BR112014030436A2/pt not_active IP Right Cessation
- 2013-06-05 EP EP19150395.2A patent/EP3530283A1/de not_active Withdrawn
- 2013-06-05 IN IN10408DEN2014 patent/IN2014DN10408A/en unknown
- 2013-06-05 WO PCT/AU2013/000589 patent/WO2013181696A1/en active Application Filing
-
2014
- 2014-12-04 IL IL236092A patent/IL236092A0/en unknown
- 2014-12-10 ZA ZA2014/09076A patent/ZA201409076B/en unknown
-
2015
- 2015-04-20 HK HK15103819.6A patent/HK1203358A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20150021088A (ko) | 2015-02-27 |
AU2013271338B2 (en) | 2018-05-24 |
ZA201409076B (en) | 2017-06-28 |
CA2875683A1 (en) | 2013-12-12 |
CN104717971A (zh) | 2015-06-17 |
EP3530283A1 (de) | 2019-08-28 |
NZ702721A (en) | 2016-11-25 |
BR112014030436A2 (pt) | 2017-09-26 |
EP2854837A1 (de) | 2015-04-08 |
US20150150963A1 (en) | 2015-06-04 |
IL236092A0 (en) | 2015-01-29 |
WO2013181696A1 (en) | 2013-12-12 |
SG11201408101TA (en) | 2015-01-29 |
JP2015520175A (ja) | 2015-07-16 |
AU2013271338A1 (en) | 2015-01-15 |
HK1203358A1 (en) | 2015-10-30 |
EP2854837A4 (de) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
MX2018009990A (es) | Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r. | |
GB2540694A (en) | CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies | |
MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
EA201890782A1 (ru) | Способ перенацеливания t-клеток для лечения инфекции hiv | |
MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
WO2012069568A3 (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
MX346475B (es) | Peptidos inmunogenicos monomericos y multimericos. | |
GB201009273D0 (en) | Novel vaccine | |
WO2013070776A8 (en) | Neutralizing gp41 antibodies and their use | |
WO2007144720A3 (en) | Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients | |
WO2012047267A3 (en) | Polyvalent immunogen | |
WO2011103417A3 (en) | Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response | |
EA201290956A1 (ru) | Вакцина против вич | |
WO2012145238A3 (en) | Methods for reducing an adverse immune response to a foreign antigen in human using cd4-binding molecules | |
EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
BR112017003332A2 (pt) | uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica | |
WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
IN2014KN02740A (de) | ||
WO2011100408A3 (en) | Serologic correlates of protection against bacillis anthracis infection | |
IN2014DN10408A (de) | ||
PH12018500645A1 (en) | Hiv antibody compositions and methods of use | |
WO2015048796A3 (en) | Mosaic hiv envelope immunogenic polypeptides | |
AU2013235442A8 (en) | Stable peptide mimetics of the HIV-1 gp41 pre-hairpin intermediate |